Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 20, 2026.

Roles of PLODs in Collagen Synthesis and Cancer Progression

Yifei Qi, Ren Xu

Frontiers in Cell and Developmental Biology · 2018 · Review

doi:10.3389/fcell.2018.00066

Abstract

genes. Expression of PLODs is regulated by multiple cytokines, transcription factors and microRNAs. Dysregulation of PLODs promotes cancer progression and metastasis, suggesting that targeting PLODs is potential strategy for cancer treatment. Here, we summarize the recent progress in the investigation of function and regulation of PLODs in normal tissue development and disease progression, especially in cancer.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 20, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Collagen is one of the major components of extracellular matrix. The collagen-cell interaction induces biochemical and biophysical signals, which is essentially for normal tissue function and cancer progression (Egeblad et al.,; Xiong and Xu, ). The collagen family contains 28 members (Heino, ) and can be divided into two groups: fibrillar collagen (type I, II, III, V, XI) and non-fibrillar collagen (type IV, VIII, X, IX, XII, XIV, XV, XVIII, XIX, XXI). Collagen is the most abundant protein in our body, and presents in both normal tissues and cancer. Type I collagen, the most common type fibrillar, has been identified in many tissues, including skin, tendon, vascular ligature and bone; while type II collagen is the main collagenous component of cartilage. Non-fibrillar type IV collagen is required for basement membrane formation (Paulsson, ). Cell-collagen interaction induces cellular signaling via integrin [included α1β1 (Tulla et al.,; Hamaia et al., ), α2β1 (Tulla et al.,; Carafoli et al., ), α10β1 (Camper et al., ) and α11β1 (Tiger et al.,; Hamaia et al., )], discoidin domain receptors (Leitinger,, ) and Leukocyte-Associated Immunoglobulin-Like Receptor-1 (Rygiel et al.,; Kim et al., ). Collagen regulates tumor progression by modulating cancer cell migration, invasion (Xiong et al., ), proliferation (Pollard, ), survival (Cheon et al., ) and metastasis (Oudin et al.,; Sun et al., ).

All collagen is composed of a triple helix, and the most common motif of the triple helix sequence is Gly-X-Y (X and Y represent proline or hydroxyproline) (Albaugh et al., ). Collagen is synthesized in the rough endoplasmic reticulum (ER) as a precursor (Nimni, ). After peptide bond formation, proline and lysyl hydroxylation is catalyzed by prolyl 4-hydroxylase (P4H) and procollagen-lysine,2-oxoglutarate 5-dioxygenase (PLOD). The hydroxylation of lysyl residues is one of the critical steps of collagens biosynthesis. It usually occurs in the Y position of the repeating Gly-X-Y motif (Barnes et al.,; Valtavaara et al., ). Three PLODs (PLOD1, PLOD2 and PLOD3) has been identified, catalyzing the lysyl hydroxylation to hydroxylysine (Hausmann,; Rhoads and Udenfriend,; Kivirikko Ki,; Rautavuoma et al., ).

Hydroxylysine residue is critical for the formation of covalent cross-links and collagen glycosylation (Valtavaara et al., ). PLODs catalyze hydroxylation of lysine (Lys) intracellularly before collagen is secreted, and then lysyl oxidase (LOX) binds to hydroxylysine (Hyl) residues in the extracellular collagen fibers and induces the cross-link formation (Saito and Marumo, ). This enzyme dependent collagen crosslinking stabilizes newly formed collagen fibers and enhances the stiffness of the matrix. During collagen maturation, the hydroxylysine residues in the helix region are often modified by the O-linked glycosylation. These reactions are catalyzed by hydroxylysine galactosyltransferase (GT) and galactosylhydroxylysine -glucosyltransferase (GGT) (Shinkai and Yonemasu,; Yamauchi and Sricholpech, ). The enzymatic activities of GT and GGT are found in multifunctional PLOD3, but not in PLOD1 and PLOD2 (Heikkinen et al., ). Mutations of the human PLOD3 gene lead to congenital disorders affecting connective tissues of various organs (Salo et al., ), suggesting that GGT activity of PLOD3 is crucial for the normal function of collagen.

The mutation or overexpression of PLODs has been detected in many human diseases. The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS type VIA) is due to a mutation in the PLOD1 gene (Rohrbach et al.,; Zahed-Cheikh et al., ). The reduction of PLOD3 protein at the basement membrane is associated with recessive dystrophic epidermolysis bullosa (RDEB) progression (Watt et al., ). The overexpression of PLOD2 is detected in many types of cancer. Therefore, investigating the function and the regulation of PLODs in normal organ development and disease progression may identify potential targets for the treatment of collagen-related diseases.

Structure of PLODs

Proteins in the PLOD family are highly homologous; the overall identity in protein sequences among PLOD1, 2 and 3 is 47% (Valtavaara et al., ). PLOD protein has binding sites for cofactor Fe2+ and L-ascorbate. It also contains 26 amino acid signal peptide and a Prolyl 4-hydroxylase alpha subunit homologs domain (Figure 1). PLOD1 gene locates on chromosome 1p36 (Tasker et al., ) and is composed by 19 exons (Giunta et al., ). Collagen hydroxylation catalyzed by PLOD1 is crucial for bone mineral density (BMD) and bone quality (Tasker et al., ). PLOD2 gene is at chromosome 3q23-q24 (Szpirer et al., ) and also contains 19 exons. Two splice variants (LH2a and LH2b) have been identified in the PLOD2 gene; LH2b differs from LH2a by incorporating the small exon 13A (Valtavaara, ). PLOD2 plays a key role in formation of stabilized collagen cross-links (Gilkes et al., ). PLOD3 gene is localized to chromosome 7q36 (Hautala et al.,; Szpirer et al.,; Valtavaara et al., ), and PLOD3 activity is important for the biosynthesis of type IV and VI collagen (Rautavuoma et al.,; Sipilä et al., ). PLOD1 and PLOD3 hydroxylate lysyl residues in the collagen triple helix, whereas PLOD2 (LH2b) hydroxylate lysyl residues in the telopeptides of collagen (Valtavaara, ). PLOD3 has glycosylation activity that induces either monosaccharide or disaccharide attaching to collagen hydroxylysines (Valtavaara, ).

Regulation of PLOD expression

PLOD expression is mainly regulated at the transcription level. A number of cytokines, signaling pathways, and microRNAs have been identified to be involved in transcriptional regulation of PLODs (Table 1). PLOD2 is induced by hypoxia-inducible factor-1α (HIF-1α) under hypoxia condition, which in turn enhance hypoxia-induced Epithelial-Mesenchymal Transition (EMT) phenotypes in glioma cells (Song et al., ) and breast cancer cells (Gilkes et al., ). In addition, hypoxia-inducible factor 1 (HIF-1) also activates transcription of PLOD1 in breast cancer cells; however, function PLOD2 is more important for HIF-1-induced cancer progression (Gilkes et al., ). PLOD2 is also directly regulated by miR-26a-5p and miR-26b-5p, and PLOD2 expression is a potential prognostic marker for patients with bladder cancer (Miyamoto et al., ) and renal cell carcinoma (Kurozumi et al., ). TGF-β signaling is another important regulator of PLOD2 expression (Remst et al., ). SP1 and SMAD3, as downstream targets of TGF-β signaling, recruit histone modifying enzymes to the PLOD2 promoter region and induced PLOD2 transcription (Gjaltema et al., ). In addition, transcription factor E2Fs (Hollern et al., ) and FOXA1 (Du et al., ) have been identified as regulators of PLOD2 during cancer progression (Figure 2).

Regulation of PLOD1 and PLOD3 expression is not well-investigated compared to PLOD2. Differential display analysis identified PLOD1 as a potential target gene of TNFα in human chondrocyte-like cells (Ah-Kim et al., ). Using chromatin immunoprecipitation and luciferase reporter assay, Hjalt showed that PITX2 directly regulates PLOD1 expression by binding to the promoter region. Inactivation of this pathway may cause the Rieger syndrome (Hjalt et al., ). One report show that miR-663a reduces PLOD3 expression by targeting to 3'-UTR of PLOD3 mRNA, subsequently reducing extracellular accumulation of type IV collagen (Amodio et al., ).

ACHP (2-Amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-(4-piperidinyl)−3 pyridinecarbonitrile), a selective inhibitor of IκB kinase, suppresses expression of all three PLOD genes in dermal fibroblasts, but not in lung fibroblasts (Mia and Bank, ). Therefore, activation of NF-kB pathway may induce PLOD expression in certain types of cells. Treatment with bone morphogenetic protein-2 (BMP-2) and TGF-β1 induces PLOD1 expression in adipose tissue-derived mesenchymal stem cells (AT-MSCs). Interestingly, neither BMP-2 nor TGF-β1 can induce PLOD2 expression (Knippenberg et al., ). Given the crucial function of PLODs in collagen synthesis, further defining the molecular mechanisms by which PLOD expression is regulated may significantly expand our understanding of collagen-related disease progression.

Physiological functions of PLODs

Collagen is the major component of connective tissues and maintains the structural integrity and the stability of tissues and organs (Patino et al., ). The hydroxylysine residues provide attachment sites for the carbohydrates and tensile strength and mechanical stability for the collagen fibrils (Rautavuoma et al., ). The abnormal expression or mutation of PLODs is associated with collagen-related diseases, such as Kyphoscoliotic type of EDS VIA (Pousi et al.,; Giunta et al.,; Abdalla et al.,; van Dijk et al.,; Zahed-Cheikh et al., ), Bruck Syndrome (BS) (Gistelinck et al., ) and RDEB (Watt et al., ) (Table 2). PLOD1 regulates the hydroxylation of lysyl residues on collagen type V. The duplication of the exon 10 to exon 16 region of PLOD1 (p.Glu326_Lys585dup) gene (Pousi et al.,; Giunta et al., ) and two mutations on Gln208 and Tyr675 cause the loss function of PLOD1, which may lead to EDS VIA (Abdalla et al.,; van Dijk et al., ). In addition, PLOD1 has been identified as a susceptibility gene for reduced BMD (Tasker et al.,; Yamada and Shimokata, ).

Dysregulation of PLOD2 is associated with brain arteriovenous malformations and cancer progression. PLOD2 is overexpressed in brain arteriovenous malformations (bAVM), and the levels of PLOD2 expression correlated with bAVM size (Neyazi et al., ). PLOD2 mutant zebrafish display molecular and tissue abnormalities in the musculoskeletal system that are concordant with clinical findings in BS patients (Gistelinck et al., ). There is evidence that the levels of mature hydroxylysine aldehyde-derived cross-links typical for skeletal tissues is increased in vein graft disease, this is accompanied by upregulation of PLOD2 (Kahle et al., ). Furthermore, increased PLOD2 expression has been detected in the macroscopically injured region of the capsule, and upregulation of TGF-β1, TGFβR1, and PLOD2 is likely related to the disease progression (Belangero et al., ).

It has been shown that PLOD3 mutations are associated with the connective tissue disorder (Salo et al., ). Analysis of PLOD3 knock-out embryos and cells indicate that loss of PLOD2 reduces glycosylated hydroxylysines on type IV and VI collagen with abnormal distribution (Sipilä et al., ). Reduced glycosylation may inhibit the tetramerization and secretion of type VI collagen. Another function of PLOD3 is to glucosylate galactosylhydroxylysine residues in type I collagen in osteoblasts. The G-Hyl glucosylation induced by PLOD3 is crucial for collagen fibrillogenesis in vitro (Sricholpech et al., ).

PLODs in cancer progression and metastasis

Increased collagen deposition and cross-linking promote cancer development and progression by enhancing cancer cell migration, invasion and proliferation (Provenzano et al.,,; Levental et al.,; Zhu et al., ). Therefore, PLODs may contribute to cancer progression by modulating collagen cross-link and maturation.

Increased PLOD expression has been detected in many types of cancer. The PLOD2 expression level is significantly upregulated in breast cancer compared to normal mammary tissue, and the upregulation correlates with short disease-related survival (Gjaltema et al., ). In esophageal squamous-cell carcinoma (ESCC), expression of the tumor suppressor gene esophageal cancer-related gene 4 has a negative association with PLOD1 and PLOD2 (Li et al., ). The PLOD2 expression is significantly correlated disease-free survival and tumor size in hepatocellular carcinoma (HCC) (Noda et al., ). PLOD3 is overexpressed in HCC (Elsemman et al.,; Shen et al., ) and is a potential diagnosis marker for early-stage HCC (Shen et al., ). Knockdown of PLOD3 suppresses liver tumor incidence as well as tumor growth rates in spontaneous mouse HCC model (Shen et al., ). Nicastri used a quantitative proteomic technique and identified 54 up-regulated glycoproteins in colorectal cancer samples, including PLOD2 and PLOD3 (Nicastri et al., ).

Increased PLOD2 expression is crucial for tumor invasion and metastasis (Figure 2). For instance, silencing PLOD2 expression in the breast cancer cell line MDA-MB 231 reduces cancer metastasis and collagen deposition in the primary tumor tissue; interestingly, PLOD2 expression has little effect on the primary tumor growth (Gilkes et al., ). Hypoxia- and TGF-β1-induced PLOD2 expression promotes the migratory, invasive and adhesive capacities of cervical cancer cells by promoting EMT and the formation of focal adhesion (Remst et al.,; Xu et al., ). In HIF-1α-deficient tumors, ectopic PLOD2 expression restores the migration and metastatic potential, and inhibition of PLOD2 activity suppresses the tumor metastases (Eisinger-Mathason et al., ). Although HIF-1 induces expression of PLOD1 and PLOD2, PLOD2 expression in breast cancer cells is more important for fibrillary collagen formation, tumor stiffness and cancer metastasis to lymph nodes and lungs (Gilkes et al., ).

Function of PLOD2 in lung cancer progression differs slightly from breast cancer; ectopic expression of PLOD2 enhances both primary cancer growth and metastasis (Chen et al., ). PLOD2 hydroxylates telopeptidyl lysine residues on collagen, subsequently increasing the level of hydroxylysine aldehyde–derived collagen cross-links (HLCCs) and lowering levels of lysine aldehyde–derived cross-links in lung cancer tissue (Chen et al., ). Recent study also reveal that PLOD2 expression induces PI3K/AKT signaling in glioma (Song et al., ) and non-small-cell lung cancer (NSCLC) (Du et al., ); activation of the PI3K pathway may contribute to increased cell proliferation, migration and invasion.

It is well established that PLOD2 protein locates in ER (Liefhebber et al., ). However, a recent study shows that PLOD2 protein can be secreted by lung cancer cells and induce collagen remodeling (Chen et al., ). Addition of recombinant PLOD2 to the extracellular space promotes HLCC formation in the extracellular matrix, suggesting that secreted PLOD2 is functional (Chen et al., ). However, function of secreted PLOD2 in cancer development and progression remains to be determined.

Cancer associated fibroblasts (CAFs) and stellate cells, as the major source of ECM production in the tumor microenvironment, promote tumor cell invasion and migration through the PLOD2-induced collagen cross-link (Bozóky et al.,; Pankova et al., ). PLOD2 is highly expressed in CAFs; silencing PLOD2 expression in CAFs significantly reduced the tumor invasion and metastasis (Pankova et al., ). Knockdown of PLOD2 in pancreatic stellate cells inhibits directional migration of cancer cells within the matrices by constructing an insensitive microenvironment of three-dimensional (3D) matrices to tumor migration (Sada et al., ). These results indicate that PLOD2 expressed in stromal cells is crucial for cancer progression.

Future direction

Loss of function mutations and abnormal PLOD expression are involved in many collagen-related diseases. Impairment of PLOD1 function contributes the development of Kyphoscoliotic type of EDS. Mutations of PLOD3 cause the connective tissue disorder (Salo et al., ). Many studies demonstrate that increased PLOD2 and PLOD3 expression is required for cancer progression and metastasis. Therefore, targeting PLOD is a potential therapeutic strategy for cancer and other collagen-related diseases. Unfortunately, there is no potent PLOD inhibitor available. Since the client protein and function of PLOD1, PLOD2, and PLOD3 in collagen synthesis are different, it is important to develop specific inhibitors for PLOD to halt cancer progression. Another strategy to inhibit PLOD activity in cancer tissue is to reduce PLOD expression; therefore, further understanding how PLOD is regulated during cancer development may identify signaling pathways to target PLOD.

Author contributions

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 84

  1. 1.

    Abdalla E. M. Rohrbach M. Bürer C. Kraenzlin M. El-Tayeby H. Elbelbesy M. F.. (2015 ). Kyphoscoliotic type of Ehlers-Danlos Syndrome (EDS VIA) in six Egyptian patients presenting with a homogeneous clinical phenotype. Eur. J. Pediatr. 174, 105–112.

    Not in our library10.1007/s00431-014-2429-9

  2. 2.

    Ah-Kim H. Zhang X. Islam S. Sofi J. I. Glickberg Y. Malemud C. J.. (2000 ). Tumour necrosis factor α enhances the expression of hydroxyl lyase, cytoplasmic antiproteinase-s and a dual specificity kinase TTK in human chondrocyte-like cells. Cytokine 12, 142–150.

    Not in our library10.1006/cyto.1999.0539

  3. 3.

    Albaugh V. L. Mukherjee K. Barbul A. (2017 ). Proline precursors and collagen synthesis: biochemical challenges of nutrient supplementation and wound healing. J. Nutr. 147, 2011–2017.

    Not in our library10.3945/jn.117.256404

  4. 4.

    Amodio G. Sasso E. D'ambrosio C. Scaloni A. Moltedo O. Franceschelli S.. (2016 ). Identification of a microRNA (miR-663a) induced by ER stress and its target gene PLOD3 by a combined microRNome and proteome approach. Cell Biol. Toxicol. 32, 285–303.

    Not in our library10.1007/s10565-016-9335-z

  5. 5.

    Barnes M. J. Constable B. J. Morton L. F. Royce P. M. (1974 ). Age-related variations in hydroxylation of lysine and proline in collagen. Biochem. J. 139, 461–468.

    Not in our library10.1042/bj1390461

  6. 6.

    Belangero P. S. Leal M. F. Cohen C. Figueiredo E. A. Smith M. C. Andreoli C. V.. (2016 ). Expression analysis of genes involved in collagen cross-linking and its regulation in traumatic anterior shoulder instability. J. Orthop. Res. 34, 510–517.

    Not in our library10.1002/jor.22984

  7. 7.

    Bozóky B. Savchenko A. Csermely P. Korcsmáros T. Dúl Z. Pontén F.. (2013 ). Novel signatures of cancer-associated fibroblasts. Int. J. Cancer 133, 286–293.

    Not in our library10.1002/ijc.28035

  8. 8.

    Camper L. Hellman U. Lundgren-Åkerlund E. (1998 ). Isolation, cloning, and sequence analysis of the Integrin Subunit α10, a β1-associated collagen binding integrin expressed on chondrocytes. J. Biol. Chem. 273, 20383–20389.

    Not in our library10.1074/jbc.273.32.20383

  9. 9.

    Carafoli F. Hamaia S. W. Bihan D. Hohenester E. Farndale R. W. (2013 ). An activating mutation reveals a second binding mode of the integrin α2 i domain to the GFOGER motif in collagens. PLoS ONE 8:e69833.

    Not in our library10.1371/journal.pone.0069833

  10. 10.

    Chen Y. Guo H. Terajima M. Banerjee P. Liu X. Yu J.. (2016 ). Lysyl hydroxylase 2 is secreted by tumor cells and can modify collagen in the extracellular space. J. Biol. Chem. 291, 25799–25808.

    Not in our library10.1074/jbc.m116.759803

  11. 11.

    Chen Y. Terajima M. Yang Y. Sun L. Ahn Y.-H. Pankova D.. (2015 ). Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J. Clin. Invest. 125, 1147–1162.

    Not in our library10.1172/jci74725

  12. 12.

    Cheon D.-J. Tong Y. Sim M.-S. Dering J. Berel D. Cui X.. (2014 ). A collagen-remodeling gene signature regulated by tgf-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin. Cancer Res. 20, 711–723.

    Not in our library10.1158/1078-0432.ccr-13-1256

  13. 13.

    Chong M. S. Goh L. K. Lim W. S. Chan M. Tay L. Chen G.. (2013 ). Gene expression profiling of peripheral blood leukocytes shows consistent longitudinal downregulation of TOMM40 and upregulation of KIR2DL5A, PLOD1, and SLC2A8 among fast progressors in early Alzheimer's disease. J. Alzheimers Dis. 34, 399–405.

    Not in our library10.3233/jad-121621

  14. 14.

    Conklin M. W. Eickhoff J. C. Riching K. M. Pehlke C. A. Eliceiri K. W. Provenzano P. P.. (2011 ). Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am. J. Pathol. 178, 1221–1232.

    Not in our library10.1016/j.ajpath.2010.11.076

  15. 15.

    Du H. Chen Y. Hou X. Huang Y. Wei X. Yu X.. (2017 ). PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC. Cell Death Dis. 8:e3143.

    Not in our library10.1038/cddis.2017.553

  16. 16.

    Egeblad M. Rasch M. G. Weaver V. M. (2010 ). Dynamic interplay between the collagen scaffold and tumor evolution. Curr. Opin. Cell Biol. 22, 697–706.

    Not in our library10.1016/j.ceb.2010.08.015

  17. 17.

    Eisinger-Mathason T. S. K. Zhang M. Qiu Q. Skuli N. Nakazawa M. S. Karakasheva T.. (2013 ). Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov. 3, 1190–1205.

    Not in our library10.1158/2159-8290.cd-13-0118

  18. 18.

    Elsemman I. E. Mardinoglu A. Shoaie S. Soliman T. H. Nielsen J. (2016 ). Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism. Mol. Biosyst. 12, 1496–1506.

    Not in our library10.1039/c5mb00827a

  19. 19.

    Gilkes D. M. Bajpai S. Chaturvedi P. Wirtz D. Semenza G. L. (2013a ). Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic Conditions by Inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J. Biol. Chem. 288, 10819–10829.

    Not in our library10.1074/jbc.m112.442939

  20. 20.

    Gilkes D. M. Bajpai S. Wong C. C. Chaturvedi P. Hubbi M. E. Wirtz D.. (2013b ). Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol. Cancer Res. 11, 456–466.

    Not in our library10.1158/1541-7786.mcr-12-0629

  21. 21.

    Gistelinck C. Witten P. E. Huysseune A. Symoens S. Malfait F. Larionova D.. (2016 ). Loss of type I collagen telopeptide lysyl hydroxylation causes musculoskeletal abnormalities in a zebrafish model of bruck syndrome. J. Bone Miner. Res. 31, 1930–1942.

    Not in our library10.1002/jbmr.2977

  22. 22.

    Giunta C. Randolph A. Steinmann B. (2005 ). Mutation analysis of the PLOD1 gene: an efficient multistep approach to the molecular diagnosis of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA). Mol. Genet. Metab. 86, 269–276.

    Not in our library10.1016/j.ymgme.2005.04.014

  23. 23.

    Gjaltema R. a F. De Rond S. Rots M. G. Bank R.A. (2015 ). procollagen lysyl hydroxylase 2 expression is regulated by an alternative downstream transforming growth factor β-1 activation mechanism. J. Biol. Chem. 290, 28465–28476.

    Not in our library10.1074/jbc.m114.634311

  24. 24.

    Hamaia S. W. Pugh N. Raynal N. Némoz B. Stone R. Gullberg D.. (2012 ). Mapping of potent and specific binding motifs, glogen and gvogea, for integrin α1β1 using collagen toolkits, I. I., and III. J. Biol. Chem. 287, 26019–26028.

    Not in our library10.1074/jbc.m112.353144

  25. 25.

    Hausmann E. (1967 ). Cofactor requirements for the enzymatic hydroxylation of lysine in a polypeptide precursor of collagen. Biochim. Biophys. Acta 133, 591–593.

    Not in our library10.1016/0005-2795(67)90566-1

  26. 26.

    Hautala T. Byers M. G. Eddy R. L. Shows T. B. Kivirikko K. I. Myllyla R. (1992 ). Cloning of human lysyl hydroxylase: complete cDNA-derived amino acid sequence and assignment of the gene (PLOD) to chromosome 1p36.3 → p36.2. Genomics 13, 62–69.

    Not in our library10.1016/0888-7543(92)90202-4

  27. 27.

    Heikkinen J. Risteli M. Wang C. Latvala J. Rossi M. Valtavaara M.. (2000 ). Lysyl hydroxylase 3 is a multifunctional protein possessing collagen glucosyltransferase activity. J. Biol. Chem. 275, 36158–36163.

    Not in our library10.1074/jbc.m006203200

  28. 28.

    Heino J. (2007 ). The collagen family members as cell adhesion proteins. Bioessays 29, 1001–1010.

    Not in our library10.1002/bies.20636

  29. 29.

    Hjalt T. A. Amendt B. A. Murray J. C. (2001 ). Pitx2 regulates procollagen lysyl hydroxylase (plod) gene expression: implications for the pathology of Rieger syndrome. J. Cell Biol. 152, 545–552.

    Not in our library10.1083/jcb.152.3.545

  30. 30.

    Hollern D. P. Honeysett J. Cardiff R. D. Andrechek E. R. (2014 ). The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer. Mol. Cell. Biol. 34, 3229–3243.

    Not in our library10.1128/mcb.00737-14

  31. 31.

    Kahle B. Schmidtke C. Hunzelmann N. Bartels C. Sievers H. H. Steenbock H.. (2016 ). The extracellular matrix signature in vein graft disease. Can. J. Cardiol. 32, 1008e11–1008e17.

    Not in our library10.1016/j.cjca.2015.11.014

  32. 32.

    Kim S. Easterling E. R. Price L. C. Smith S. L. Coligan J. E. Park J.-E.. (2017 ). The role of leukocyte-associated ig-like receptor-1 in suppressing collagen-induced arthritis. J. Immunol. 199, 2692–2700.

    Not in our library10.4049/jimmunol.1700271

  33. 33.

    Kivirikko Ki P. T. (1998 ). Collagen hydroxylases and the protein disulfide isomerase subunit of prolyl 4-hydroxylases. Adv. Enzymol. Relat. Areas Mol. Biol. 72, 325–398.

    Not in our library10.1002/9780470123188.ch9

  34. 34.

    Knippenberg M. Helder M. N. Doulabi B. Z. Bank R. A. Wuisman P. I. J. M. Klein-Nulend J. (2009 ). Differential effects of bone morphogenetic protein-2 and transforming growth factor-β1 on gene expression of collagen-modifying enzymes in human adipose tissue–derived mesenchymal stem cells. Tissue Eng. Part A 15, 2213–2225.

    Not in our library10.1089/ten.tea.2007.0184

  35. 35.

    Kurozumi A. Kato M. Goto Y. Matsushita R. Nishikawa R. Okato A.. (2016 ). Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma. Int. J. Oncol. 48, 1837–1846.

    Not in our library10.3892/ijo.2016.3440

  36. 36.

    Leitinger B. (2003 ). Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2: identification of collagen binding sites in DDR2. J. Biol. Chem. 278, 16761–16769.

    Not in our library10.1074/jbc.m301370200

  37. 37.

    Leitinger B. (2011 ). Transmembrane collagen receptors. Annu. Rev. Cell Dev. Biol. 27, 265–290.

    Not in our library10.1146/annurev-cellbio-092910-154013

  38. 38.

    Levental K. R. Yu H. Kass L. Lakins J. N. Egeblad M. Erler J. T.. (2009 ). Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891–906.

    Not in our library10.1016/j.cell.2009.10.027

  39. 39.

    Li L. Wang W. Li X. Gao T. (2017 ). Association of ECRG4 with PLK1, CDK4, PLOD1 and PLOD2 in esophageal squamous cell carcinoma. Am. J. Transl. Res. 9, 3741–3748.

    Not in our library

  40. 40.

    Liefhebber J. M. P. Punt S. Spaan W. J. M. Van Leeuwen H. C. (2010 ). The human collagen beta(1-O)galactosyltransferase, GLT25D1, is a soluble endoplasmic reticulum localized protein. BMC Cell Biol. 11:33.

    Not in our library10.1186/1471-2121-11-33

  41. 41.

    Paulsson M. (1992 ). Basement membrane proteins: structure, assembly, and cellular interactions. Crit. Rev. Biochem. Mol. Biol. 27, 93–127.

    Not in our library10.3109/10409239209082560

  42. 42.

    Mia M. M. Bank R. A. (2015 ). The IκB kinase inhibitor ACHP strongly attenuates TGFβ1-induced myofibroblast formation and collagen synthesis. J. Cell. Mol. Med. 19, 2780–2792.

    Not in our library10.1111/jcmm.12661

  43. 43.

    Miyamoto K. Seki N. Matsushita R. Yonemori M. Yoshino H. Nakagawa M.. (2016 ). Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer. Br. J. Cancer 115, 354–363.

    Not in our library10.1038/bjc.2016.179

  44. 44.

    Neyazi B. Tanrikulu L. Wilkens L. Hartmann C. Stein K.-P. Dumitru C. A.. (2017 ). Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 2 expression in brain arteriovenous malformations and its association with brain arteriovenous malformation size. World Neurosurg. 102, 79–84.

    Not in our library10.1016/j.wneu.2017.02.116

  45. 45.

    Nicastri A. Gaspari M. Sacco R. Elia L. Gabriele C. Romano R.. (2014 ). N-Glycoprotein analysis discovers new up-regulated glycoproteins in colorectal cancer tissue. J. Proteome Res. 13, 4932–4941.

    Not in our library10.1021/pr500647y

  46. 46.

    Nimni M. E. (1983 ). Collagen: structure, function, and metabolism in normal and fibrotic tissues. Semin. Arthritis Rheum. 13, 1–86.

    Not in our library10.1016/0049-0172(83)90024-0

  47. 47.

    Noda T. Yamamoto H. Takemasa I. Yamada D. Uemura M. Wada H.. (2012 ). PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Liver Int. 32, 110–118.

    Not in our library10.1111/j.1478-3231.2011.02619.x

  48. 48.

    Oudin M. J. Jonas O. Kosciuk T. Broye L. C. Guido B. C. Wyckoff J.. (2016 ). Tumor cell–driven extracellular matrix remodeling drives haptotaxis during metastatic progression. Cancer Discov. 6, 516–531.

    Not in our library10.1158/2159-8290.cd-15-1183

  49. 49.

    Pankova D. Chen Y. Terajima M. Schliekelman M. J. Baird B. N. Fahrenholtz M.. (2016 ). Cancer-associated fibroblasts induce a collagen cross-link switch in tumor stroma. Mol. Cancer Res. 14, 287–295.

    Not in our library10.1158/1541-7786.mcr-15-0307

  50. 50.

    Patino M. G. Neiders M. E. Andreana S. Noble B. Cohen R. E. (2002 ). Collagen: an overview. Implant Dent. 11, 280–285.

    Not in our library10.1097/00008505-200207000-00014

  51. 51.

    Pollard J. W. (2004 ). Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71–78.

    Not in our library10.1038/nrc1256

  52. 52.

    Pousi B. Hautala T. Heikkinen J. Pajunen L. Kivirikko K. I. Myllylä R. (1994 ). Alu-Alu recombination results in a duplication of seven exons in the lysyl hydroxylase gene in a patient with the type VI variant of Ehlers-Danlos syndrome. Am. J. Hum. Genet. 55, 899–906.

    Not in our library10.1016/0945-053x(94)90130-9

  53. 53.
    Collagen reorganization at the tumor-stromal interface facilitates local invasion · 2006
    No notice
  54. 54.
    Collagen density promotes mammary tumor initiation and progression · 2008
    No notice
  55. 55.
    Identification and validation of genes involved in cervical tumourigenesis · 2011
    No notice
  56. 56.

    Rautavuoma K. Takaluoma K. Sormunen R. Myllyharju J. Kivirikko K. I. Soininen R. (2004 ). Premature aggregation of type IV collagen and early lethality in lysyl hydroxylase 3 null mice. Proc. Natl. Acad. Sci. U.S.A. 101, 14120–14125.

    Not in our library10.1073/pnas.0404966101

  57. 57.

    Remst D. F. G. Blaney Davidson E. N. Vitters E. L. Bank R. A. Van Den Berg W. B. Van Der Kraan P. M. (2014 ). TGF-ß induces Lysyl hydroxylase 2b in human synovial osteoarthritic fibroblasts through ALK5 signaling. Cell Tissue Res. 355, 163–171.

    Not in our library10.1007/s00441-013-1740-5

  58. 58.

    Rhoads R. E. Udenfriend S. (1968 ). Decarboxylation of alpha-ketoglutarate coupled to collagen proline hydroxylase. Proc. Natl. Acad. Sci. U.S.A. 60, 1473–1478.

    Not in our library10.1073/pnas.60.4.1473

  59. 59.

    Rohrbach M. Vandersteen A. Yiş U. Serdaroglu G. Ataman E. Chopra M.. (2011 ). Phenotypic variability of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA): clinical, molecular and biochemical delineation. Orphanet J. Rare Dis. 6, 46–46.

    Not in our library10.1186/1750-1172-6-46

  60. 60.

    Rygiel T. P. Stolte E. H. De Ruiter T. Van De Weijer M. L. Meyaard L. (2011 ). Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1. Mol. Immunol. 49, 402–406.

    Not in our library10.1016/j.molimm.2011.09.006

  61. 61.

    Sada M. Ohuchida K. Horioka K. Okumura T. Moriyama T. Miyasaka Y.. (2016 ). Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility. Cancer Lett. 372, 210–218.

    Not in our library10.1016/j.canlet.2016.01.016

  62. 62.

    Saito M. Marumo K. (2010 ). Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos. Int. 21, 195–214.

    Not in our library10.1007/s00198-009-1066-z

  63. 63.

    Salo A. M. Cox H. Farndon P. Moss C. Grindulis H. Risteli M.. (2008 ). A connective tissue disorder caused by mutations of the Lysyl Hydroxylase 3 gene. Am. J. Hum. Genet. 83, 495–503.

    Not in our library10.1016/j.ajhg.2008.09.004

  64. 64.

    Shen Q. Eun J. W. Lee K. Kim H. S. Yang H. D. Kim S. Y. (2018 ). BANF1, PLOD3, SF3B4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma. Hepatology 67, 1360–1377.

    Not in our library10.1002/hep.29606

  65. 65.

    Shinkai H. Yonemasu K. (1979 ). Hydroxylysine-linked glycosides of human complement subcomponent C1q and various collagens. Biochem. J. 177, 847–852.

    Not in our library10.1042/bj1770847

  66. 66.

    Sipilä L. Ruotsalainen H. Sormunen R. Baker N. L. Lamandé S. R. Vapola M. (2007 ). Secretion and assembly of type, i. v., and vi collagens depend on glycosylation of hydroxylysines. J. Biol. Chem. 282, 33381–33388.

    Not in our library10.1074/jbc.m704198200

  67. 67.

    Song Y. Zheng S. Wang J. Long H. Fang L. Wang G.. (2017 ). Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma. Oncotarget 8, 41947–41962.

    Not in our library10.18632/oncotarget.16710

  68. 68.

    Sricholpech M. Perdivara I. Nagaoka H. Yokoyama M. Tomer K. B. Yamauchi M. (2011 ). Lysyl hydroxylase 3 glucosylates galactosylhydroxylysine residues in Type I collagen in osteoblast culture. J. Biol. Chem. 286, 8846–8856.

    Not in our library10.1074/jbc.m110.178509

  69. 69.

    Sun L. Wang D. Li X. Zhang L. Zhang H. Zhang Y. (2016 ). Extracellular matrix protein ITGBL1 promotes ovarian cancer cell migration and adhesion through Wnt/PCP signaling and FAK/SRC pathway. Biomed. Pharmacother. 81, 145–151.

    Not in our library10.1016/j.biopha.2016.03.053

  70. 70.

    Szpirer C. Szpirer J. Rivière M. Vanvooren P. Valtavaara M. Myllylä R. (1997 ). Localization of the gene encoding a novel isoform of lysyl hydroxylase. Mamm. Genome 8, 707–708.

    Not in our library10.1007/s003359900549

  71. 71.

    Tasker P. N. Macdonald H. Fraser W. D. Reid D. M. Ralston S. H. Albagha O. M. E. (2006 ). Association of PLOD1 polymorphisms with bone mineral density in a population-based study of women from the UK. Osteoporos. Int. 17, 1078–1085.

    Not in our library10.1007/s00198-006-0129-7

  72. 72.

    Tiger C.-F. Fougerousse F. Grundström G. Velling T. Gullberg D. (2001 ). α11β1 integrin is a receptor for interstitial collagens involved in cell migration and collagen reorganization on mesenchymal nonmuscle cells. Dev. Biol. 237, 116–129.

    Not in our library10.1006/dbio.2001.0363

  73. 73.

    Tulla M. Pentikäinen O. T. Viitasalo T. Käpylä J. Impola U. Nykvist P. (2001 ). Selective binding of collagen subtypes by integrin α1I, α2I, and α10I domains. J. Biol. Chem. 276, 48206–48212.

    Not in our library10.1074/jbc.m104058200

  74. 74.

    Valtavaara M. (1999 ). Novel Lysyl Hydroxylase Isoforms. Acta Universitatis Ouluensis A 334, 1–63.

    Not in our library

  75. 75.

    Valtavaara M. Szpirer C. Szpirer J. Myllylä R. (1998 ). Primary structure, tissue distribution, and chromosomal localization of a novel isoform of Lysyl Hydroxylase (Lysyl Hydroxylase 3). J. Biol. Chem. 273, 12881–12886.

    Not in our library10.1074/jbc.273.21.12881

  76. 76.

    van Dijk F. S. Mancini G. M. S. Maugeri A. Cobben J. M. (2017 ). Ehlers Danlos syndrome, kyphoscoliotic type due to Lysyl Hydroxylase 1 deficiency in two children without congenital or early onset kyphoscoliosis. Eur. J. Med. Genet. 60, 536–540.

    Not in our library10.1016/j.ejmg.2017.07.011

  77. 77.

    Watt S. A. Dayal J. H. S. Wright S. Riddle M. Pourreyron C. Mcmillan J. R.. (2015 ). Lysyl Hydroxylase 3 localizes to epidermal basement membrane and is reduced in patients with recessive dystrophic epidermolysis bullosa. PLoS ONE 10:e0137639.

    Not in our library10.1371/journal.pone.0137639

  78. 78.
    Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition · 2014
    No notice
  79. 79.

    Xiong G.-F. Xu R. (2016 ). Function of cancer cell-derived extracellular matrix in tumor progression. J. Cancer Metastas. Treat. 2, 357–364.

    Not in our library10.20517/2394-4722.2016.08

  80. 80.

    Xu F. Zhang J. Hu G. Liu L. Liang W. (2017 ). Hypoxia and TGF-β1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation. Cancer Cell Int. 17:54.

    Not in our library10.1186/s12935-017-0420-z

  81. 81.

    Yamada Y. A. F Shimokata H. (2007 ). Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int. J. Mol. Med. 19, 791–801.

    Not in our library10.3892/ijmm.19.5.791

  82. 82.

    Yamauchi M. Sricholpech M. (2012 ). Lysine post-translational modifications of collagen. Essays Biochem. 52, 113–133.

    Not in our library10.1042/bse0520113

  83. 83.

    Zahed-Cheikh M. T. B Coze S. Gire C. (2017 ). Kyphoscolitic type of Ehlers-Danlos syndrome with prenatal stroke. Indian Pediatr. 54, 495–497.

    Not in our library10.1007/s13312-017-1054-x

  84. 84.

    Zhu J. Xiong G. Fu H. Evers B. M. Zhou B. P. Xu R. (2015 ). Chaperone Hsp47 drives malignant growth and invasion by modulating an ECM gene network. Cancer Res. 75, 1580–1591.

    Not in our library10.1158/0008-5472.can-14-1027

Cited by papers we hold 4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.